Wegovy Perks Sustained for Years; Most Have 'CKM Syndrome'; New Adrenal Guidelines
(MedPage Today) -- One in eight U.S. adults have taken semaglutide (Ozempic, Wegovy) or another GLP-1 agonist, a KFF poll found.
Metabolic benefits of semaglutide for weight loss were sustained for several years, according to findings presented...
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news
More News: Endocrinology | Weight Loss